DE WAAL MALEFYT, RENE,BOWMAN, EDWARD, PAUL,KLEINSCHEK, MELANIE, A,BONIFACE, KATIA,BAK-JENSEN, KRISTIAN SASS,MCKENZIE, BRENT, S,MILLER, KATHY, LYNN,CUA, DANIEL, J,KASTELEIN, ROBERT, A
申请号：
NZ59791508
公开号：
NZ597915A
申请日:
2008.02.26
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
597915 Disclosed is the use of an antagonist antibody to IL-23, or an antigen binding fragment thereof in the manufacture of a medicament for treating a subject having cancer or exhibiting a flare up of an autoimmune disease, wherein the medicament is for use in a dosage regimen comprising: a) administration of the medicament in a series of one or more doses over a first time interval and b) administration of an acute phase therapeutic agent comprising an antagonist antibody or antigen binding fragment thereof that specifically binds to a cytokine or a receptor for a cytokine, selected from the group consisting of IL-1, TNF-?, IL-17A, and IL-17F in a series of one or more doses over a second time interval, wherein the second time interval (i) begins before or at the same time the first time interval begins and (ii) ends before the first time interval ends.
